Amylyx Pharmaceuticals, Inc.
AMLX
Rank in Stocks
#4500
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Share Price
$27.25
Market Cap
$3.42B
Change (1 day)
3.45%
Change (1 year)
82.27%
Country
US
Trade Amylyx Pharmaceuticals, Inc. (AMLX)
Category
Healthcare
Earnings for Amylyx Pharmaceuticals, Inc. (AMLX)
Earnings in Jun 2026 TTM: $-152.05M
According to Amylyx Pharmaceuticals, Inc. latest financial reports the company's current earnings are $-152.05M. In 2023 the company made an earning of $54.30M, an increase over its 2022 earnings that were of $-197.60M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Amylyx Pharmaceuticals, Inc. from 2019 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-152.05M | -49.68% |
| 2024 | $-302.14M | -656.45% |
| 2023 | $54.30M | -127.48% |
| 2022 | $-197.60M | 124.72% |
| 2021 | $-87.93M | 107.97% |
| 2020 | $-42.28M | 208.25% |
| 2019 | $-13.72M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -3,569.28% |
US
|
|
| $-3.09B | 1,930.31% |
US
|
|
| $-4.02B | 2,541.44% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,382.93% |
NL
|
